

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Signal regulatory protein- α (SIRPA)	<p>Patient sample and mouse studies suggest disrupting the interaction between SIRPA and CD47 could help treat AML. In a mouse model of human AML, blocking the SIRPA-CD47 interaction with a SIRPA-Fc fusion protein decreased leukemic engraftment compared with using a control IgG4-Fc fusion protein. In samples from patients with AML, the SIRPA-Fc fusion protein increased macrophage-mediated phagocytosis of AML cells compared with the control IgG4-Fc fusion protein. Trillium Therapeutics Inc. and the researchers are running additional <i>in vivo</i> efficacy and pharmacokinetic studies and plan to select a clinical development candidate within 3–4 months.</p> <p>SciBX 5(37); doi:10.1038/scibx.2012.975 Published online Sept. 20, 2012</p>	Patent application filed; licensed to Trillium Therapeutics	<p>Theocharides, A.P.A. <i>et al. J. Exp. Med.</i>; published online Sept. 3, 2012; doi:10.1084/jem.20120502</p> <p>Contact: Jean C.Y. Wang, University Health Network, Toronto, Ontario, Canada e-mail: jwang@uhnres.utoronto.ca</p>